MedTrace Logo

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2026-05-08

No results posted yet for this study

Summary

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Amivantamab

Amivantamab will be administered.

DRUG

Lazertinib

Lazertinib tablet will be administered.

DRUG

Chemotherapy: Pemetrexed

Pemetrexed will be administered.

DRUG

Chemotherapy: Carboplatin

Carboplatin will be administered.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-16
Primary Completion
2029-05-23
Completion
2030-12-26
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Finland
  • France
  • Germany
  • Greece
  • Israel
  • Italy
  • Poland
  • Portugal
  • Puerto Rico
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06667076 on ClinicalTrials.gov